Schizophrenia.com

Alkermes to seek schizophrenia drug approval after trial success

Alkermes Plc said it planned to seek U.S. marketing approval for its experimental drug to treat the symptoms of schizophrenia after it succeeded in a late-stage study, sending the company’s shares up as much as 11 percent.

The company said it would apply for marketing approval for a monthly dose of the injectable drug, aripiprazole lauroxil, in the third quarter of 2014.

1 Like

Is this resperidol?**

No - long acting Abilify. This company develops the long acting version of these medicines:
http://www.alkermes.com/Products